

The accumulation of advanced glycation endproducts in diabetes and its relation to vascular disease

Citation for published version (APA):

van Eupen, M. G. A. (2017). *The accumulation of advanced glycation endproducts in diabetes and its relation to vascular disease*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20170907mve>

Document status and date:

Published: 01/01/2017

DOI:

[10.26481/dis.20170907mve](https://doi.org/10.26481/dis.20170907mve)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

CHAPTER 9

VALORISATION ADDENDUM

VALORISATION ADDENDUM

In today's health care system, evidence-based medicine is considered to be of great importance. The interpretation of study results and their relevance and possible impact and contribution to the current health care system may be difficult to implement for the individual reader. For that purpose, the valorisation of our research results will be discussed in this addendum.

Social and economical relevance

The global prevalence of diabetes was estimated to be 8.8% in adults aged 20-79 years in 2015¹, and is believed to increase even further to 10.4%, or one in every 10 adults, in 2040¹. Due to this high prevalence, diabetes is the leading cause of renal failure in many populations². Furthermore, more than half of all non-traumatic lower limb amputations are due to diabetes^{2, 3} and diabetes is one of the leading causes of visual impairment and blindness in developed countries^{2, 4}. Besides the impact on their health and general life, the costs of health-care resources of an individual with diabetes are two to three times higher compared with individuals without diabetes^{2, 5}. Taken together, this illustrates the great impact of diabetes on modern-time society and healthcare. Therefore, studies investigating the link between diabetes and its complications, such as ours, may help to reveal opportunities to prevent or delay the development and progression of these complications. Furthermore, relevant markers of disease progression or severity may more effectively identify individuals at risk of vascular complications of diabetes.

Target group

Our main target group is the academic community. As discussed before, our research reveals potential new pathways in the development of cardiovascular disease in the general population and cardiovascular complication in diabetes. As with all studies, more new studies are needed to further investigate and validate our results. Overall, our results confirm the hypothesis that advanced glycation endproducts (AGEs) are involved in the development of multiple (cardio)vascular diseases and diabetes complications.

Implementation in daily practice

In the current health care system, diabetes is monitored by fasting glucose measurements and HbA1c, a precursor of AGEs. HbA1c provides an indication of the average glucose level over the past weeks, corresponding to the half-life of haemoglobin. This makes the HbA1c suitable to monitor the glucose burden and dietary and medicine compliance over a short term period. AGEs are accumulating on long-lived proteins in tissues, e.g. vascular tissue, the skin and vital organs. Therefore, AGE measurements are thought to represent the glucose burden over a longer period compared with HbA1c, especially when measured in tissues. Naturally, tissue biopsy specimens for the determination of AGE-levels are not suitable for daily practice. The measurement of skin autofluorescence (SAF) provides an alternative for tissue biopsies. As discussed in the introduction of this thesis, SAF has been associated with neuropathy, nephropathy and retinopathy in individuals with T1DM⁶⁻¹⁰ and T2DM^{7, 9, 11-14} and macrovascular complications in both T1DM^{7, 15, 16} and T2DM^{7, 12, 14, 15, 17, 18}. Additionally, SAF has shown to provide additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in T2DM¹⁷. In this thesis, we have shown that SAF is associated with arterial stiffness (Chapter

4), endothelial dysfunction (Chapter 5), peripheral arterial disease (Chapter 6) and cognitive impairment (Chapter 7). Since SAF is a relatively new measurement, researchers are currently studying its potential for implementation in daily practice. For now, it seems a promising new tool in the prediction of the cardiovascular risk of individuals with diabetes.

Contribution to the current field

AGE accumulation and its relation to the development of complications of diabetes is an area which is studied by numerous researchers, as shown by the multiple references throughout the former chapters. Multiple experimental studies have been and are currently being performed to look into the possible causal nature of this relation. Others have used observational studies to investigate this association in humans, such as we did in this thesis. With research presented in this thesis we believe we made some unique contributions to the current field. First, we developed and studied a new antibody against MGO-derived AGEs, which showed to be specific for THP. Second, we used state-of-the-art ultra-performance liquid chromatography (UPLC) in combination with tandem mass spectrometry or, in case of pentosidine, with high-performance liquid chromatography (HPLC) and fluorescence detection to determine different AGEs-levels in plasma. These techniques are considered to be the most accurate techniques for the measurement of AGEs at this moment. Moreover, we were able to investigate skin autofluorescence (SAF), a relatively new and promising marker of AGE accumulation, in relation to plasma AGEs and markers of vascular disease. Third, we used large cohort studies with extensively phenotyped individuals with and without diabetes, making it possible to adjust for numerous possible confounding factors. Fourth, as outcome measures in our analyses, e.g. for vascular stiffness, microvascular complications and markers endothelial dysfunction or low-grade inflammation, we did not use only one maker, but several well-known validated markers of the same processes, which makes our results more likely to reflect true associations and which strengthens our conclusions.

Future research

As described in the former chapters, we found consistent results for the associations between higher SAF and markers of vascular disease. This may implicate that AGEs are indeed implemented in the development of vascular diseases and vascular complications of diabetes. We found less homogenous results for the association between plasma AGEs and vascular diseases. Associations for plasma pentosidine were similar to SAF, but plasma CML and CEL showed nonexistent or even inverse associations. Future studies are needed to evaluate these negative associations. For now, SAF seems to provide a more consistent measurement in relation to vascular disease and vascular complications of diabetes. Prospective studies are required to investigate whether or not SAF is indeed a more valid marker of AGE accumulation than plasma AGEs.

Lutgers et al. show that SAF provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in T2DM¹⁷. However, the possible influence of the implementation of SAF measurements in daily practice for patients with diabetes on cardiovascular morbidity and mortality remains uncertain. In our health care system, individuals with diabetes are already intensively monitored and treated with regard to glycemic control, micro- and macrovascular complications and other risk factors of cardiovascular disease. Therefore, without new treatment options, the potential impact of adding SAF-measurement to the current protocol for diabetes management requires further investigation.

As AGE accumulation is proposed to be involved in the development of vascular disease, AGE-lowering therapies may be able to diminish the increased risk of CVD in individuals with increased AGE accumulation, e.g. in diabetes. Several therapeutic interventions aiming to limit AGE-related vascular damage have been investigated. Aminoguanidine is one of the most extensively studied AGE inhibitors. Aminoguanidine was shown to increase elasticity of large arteries in diabetes animal models¹⁹. However, because of disappointing results from clinical studies in individuals with diabetic nephropathy^{20, 21} and its detrimental side effects, such as deteriorated liver function and gastrointestinal toxicity²¹, it is unlikely that aminoguanidine will be implemented in anti-AGE therapy in humans. Another well-studied potential anti-AGE therapy is the cross-link breaker alagebrium (ALT-711). It has been shown that alagebrium is able to reduce large artery stiffness in different animal models, including diabetes animal models²². One double-blind RCT correspondingly showed a decrease in pulse pressure and cPWV in individuals with hypertension who received alagebrium²³. However, another double-blind RCT showed no treatment effects in individuals with chronic heart failure²⁴. Therefore, more large, specific and well-designed studies are needed to elucidate their potential effect in humans.

REFERENCES

1. International Diabetes Federation. *Idf diabetes atlas*, 7th edition. Brussels, Belgium: International Diabetes Federation. 2015
2. Alwan A. *Global status report on noncommunicable diseases 2010*. World Health Organization. 2011
3. Icks A, Haastert B, Trautner C, Giani G, Glaeske G, Hoffmann F. Incidence of lower-limb amputations in the diabetic compared to the non-diabetic population. Findings from nationwide insurance data, germany, 2005-2007. *Exp Clin Endocrinol Diabetes*. 2009;117:500-504
4. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. *Bull World Health Organ*. 2004;82:844-851
5. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G. Global healthcare expenditure on diabetes for 2010 and 2030. *Diabetes Res Clin Pract*. 2010;87:293-301
6. Araszkievicz A, Naskret D, Niedzwiecki P, Samborski P, Wierusz-Wysocka B, Zozulinska-Ziolkiewicz D. Increased accumulation of skin advanced glycation end products is associated with microvascular complications in type 1 diabetes. *Diabetes Technol Ther*. 2011;13:837-842
7. Bos DC, de Ranitz-Greven WL, de Valk HW. Advanced glycation end products, measured as skin autofluorescence and diabetes complications: A systematic review. *Diabetes Technol Ther*. 2011;13:773-779
8. Chabroux S, Canoui-Poitrine F, Reffet S, Mills-Joncour G, Morelon E, Colin C, Thivolet C. Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy. *Diabetes Metab*. 2010;36:152-157
9. Meerwaldt R, Links TP, Graaff R, Hoogenberg K, Lefrandt JD, Baynes JW, Gans RO, Smit AJ. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. *Diabetologia*. 2005;48:1637-1644
10. Orchard TJ, Lyons TJ, Cleary PA, Braffett BH, Maynard J, Cowie C, Gubitosi-Klug RA, Way J, Anderson K, Barnie A, Villavicencio S. The association of skin intrinsic fluorescence with type 1 diabetes complications in the dcct/edic study. *Diabetes Care*. 2013;36:3146-3153
11. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, Gans RO, Bilo HJ. Skin autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular complications. *Diabetes Care*. 2008;31:517-521
12. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. *Diabetes Care*. 2006;29:2654-2659
13. Monami M, Lamanna C, Gori F, Bartalucci F, Marchionni N, Mannucci E. Skin autofluorescence in type 2 diabetes: Beyond blood glucose. *Diabetes Res Clin Pract*. 2008;79:56-60
14. Tanaka K, Tani Y, Asai J, Nemoto F, Kusano Y, Suzuki H, Hayashi Y, Asahi K, Nakayama M, Miyata T, Watanabe T. Skin autofluorescence is associated with severity of vascular complications in japanese patients with type 2 diabetes. *Diabet Med*. 2012;29:492-500
15. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, Smit AJ. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. *Diabetes Care*. 2007;30:107-112
16. Conway B, Edmundowicz D, Matter N, Maynard J, Orchard T. Skin fluorescence correlates strongly with coronary artery calcification severity in type 1 diabetes. *Diabetes Technol Ther*. 2010;12:339-345
17. Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, Bilo HJ, Smit AJ. Skin autofluorescence provides additional information to the uk prospective diabetes study (ukpds) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. *Diabetologia*. 2009;52:789-797
18. Noordzij MJ, Mulder DJ, Oomen PH, Brouwer T, Jager J, Castro Cabezas M, Lefrandt JD, Smit AJ. Skin autofluorescence and risk of micro- and macrovascular complications in patients with type 2 diabetes mellitus-a multi-centre study. *Diabet Med*. 2012;29:1556-1561
19. Huijberts MS, Wolffenbittel BH, Boudier HA, Crijns FR, Kruseman AC, Poitevin P, Levy BI. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. *J Clin Invest*. 1993;92:1407-1411
20. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth JP. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. *Am J Nephrol*. 2004;24:32-40
21. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS. Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (action ii). *Control Clin Trials*. 1999;20:493-510
22. Engelen L, Stehouwer CD, Schalkwijk CG. Current therapeutic interventions in the glycation pathway: Evidence from clinical studies. *Diabetes Obes Metab*. 2012
23. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroot RC, Lakatta EG. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. *Circulation*. 2001;104:1464-1470

24. Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, Hillege HL, Voors AA. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. *Eur J Heart Fail.* 2011;13:899-908